Prices
Trump pledges his support for a change to the IRA long sought by drugmakers
IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare
Pharma’s wins and losses in Trump’s sprawling executive order on drug prices
Medicare, Medicare, Industry, drug price, Mediation, small molecule drugs, losses, IRA, Insulin, Prices
Trump’s Looming Pharmaceutical Tariffs: Uncertainty and Potential Impact
Trump, pharmaceutical tariffs, trade policy, drug prices, manufacturing, supply chain
IRA round 2 begins as drugmakers sign on to price negotiation process with CMS
Myasthenic Syndromes, Congenital, Mediation, Prices, Medicare, Ira (eukaryote), drugmakers
Novo Nordisk’s CagriSema Weight Loss Drug Trial Results Disappoint Investors
CagriSema, weight loss, clinical trial, Novo Nordisk, stock price drop, obesity treatment
Drug Pricing and the Uncertain Future of the IRA Under Trump
IRA, Transplant Registry Unified Management Program, drug price, Medicare, Mediation, repeal, Changing, Uncertainty, Prices
Novo Nordisk Slashes Wegovy Price for Cash-Paying Patients
Wegovy, price cut, Novo Nordisk, NovoCare Pharmacy, obesity treatment, semaglutide, direct-to-patient, cash-paying patients
Praxis Precision Medicines Faces Setback in Essential Tremor Drug Trial
Praxis Precision Medicines, ulixacaltamide, essential tremor, clinical trial failure, stock price drop
Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff
Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda
Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase